阿培利司联合氟维司群治疗CDK4/6抑制剂治疗后PIK3CA突变激素受体阳性晚期乳腺癌(BYLieve):一项2期多中心开放标签非对照研究的A队列
BYLieve研究A队列入组127例既往CDK4/6抑制剂联合芳香化酶抑制剂治疗后进展的PIK3CA突变、激素受体阳性、HER2阴性晚期乳腺癌患者,接受阿培利司300 mg/日联合氟维司群治疗。中心确认PIK3CA突变的119例中,6个月无疾病进展且存活比例为53.8%(95%CI 44.4-63.0)。最常见≥3级不良事件为高血糖(29%)、皮疹(10%)和斑丘疹(9%),37例(29%)发生严重不良事件,无治疗相关死亡。
要点
- A队列中心确认PIK3CA突变患者6个月无进展生存比例为53.8%(95%CI 44.4-63.0)。
- 最常见≥3级不良事件为高血糖37例(29%)、皮疹13例(10%)、斑丘疹11例(9%)。
- 37例(29%)发生严重不良事件,无治疗相关死亡。
核心结论
- BYLieve显示阿培利司联合氟维司群在CDK4/6抑制剂联合芳香化酶抑制剂治疗后进展的PIK3CA突变、激素受体阳性、HER2阴性晚期乳腺癌患者中具有活性,毒性可控。
研究设计与样本
- 正在进行的2期、多中心、开放标签、非对照研究,自全球18个国家114个研究地点入组患者。
- A队列入组既往CDK4/6抑制剂联合芳香化酶抑制剂为直接前序治疗后进展的患者,接受阿培利司300 mg/日持续口服联合氟维司群500 mg肌注(每28天周期第1天及第1周期第15天)。
- 主要终点为经中心确认PIK3CA突变患者中,按RECIST 1.1版局部评估的6个月无疾病进展且存活比例。
- 2017年8月14日至2022年7月29日(数据截止)A队列入组127例随访至少18个月的患者,其中119例中心确认PIK3CA突变。
主要发现
- 数据截止时中位随访21.8个月(IQR 10.8-37.6)。
- 119例中心确认PIK3CA突变患者中,64例(53.8%;95%CI 44.4-63.0)在6个月时无疾病进展且存活。
- 127例中最常见≥3级不良事件为高血糖37例(29%)、皮疹13例(10%)、斑丘疹11例(9%)。
- 37例(29%)发生严重不良事件,无治疗相关死亡报告。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Alpelisib, a PI3Kα-selective inhibitor and degrader, plus fulvestrant showed efficacy in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer in SOLAR-1; limited data are available in the post-cyclin-dependent kinase 4/6 inhibitor setting. BYLieve aimed to assess alpelisib plus endocrine therapy in this setting in three cohorts defined by immediate previous treatment; here, we report results from cohort A. METHODS: This ongoing, phase 2, multicentre, open-label, non-comparative study enrolled patients with hormone receptor-positive, HER2-negative, advanced breast cancer with tumour PIK3CA mutation, following progression on or after previous therapy, including CDK4/6 inhibitors, from 114 study locations (cancer centres, medical centres, university hospitals, and hospitals) in 18 countries worldwide. Participants aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 2 or less, with no more than two previous anticancer treatments and no more than one previous chemotherapy regimen, were enrolled in three cohorts. In cohort A, patients must have had progression on or after a CDK4/6 inhibitor plus an aromatase inhibitor as the immediate previous treatment. Patients received oral alpelisib 300 mg/day (continuously) plus fulvestrant 500 mg intramuscularly on day 1 of each 28-day cycle and on day 15 of cycle 1. The primary endpoint was the proportion of patients alive without disease progression at 6 months per local assessment using Response Evaluation Criteria in Solid Tumors, version 1.1, in patients with a centrally confirmed PIK3CA mutation. This trial is registered with ClinicalTrials.gov, NCT03056755. FINDINGS: Between Aug 14, 2017, and Jul 29, 2022 (data cutoff), 127 patients with at least 18 months' follow-up were enrolled into cohort A. 119 patients had a centrally confirmed PIK3CA mutation. At data cutoff, median follow-up was 21·8 months (IQR 10·8-37·6). 64 (53·8%; 95% CI 44·4-63·0) of 119 patients were alive without disease progression at 6 months. The most frequent grade 3 or worse adverse events were hyperglycaemia (37 [29%] of 127 patients), rash (13 [10%]), and rash maculopapular (11 [9%]). Serious adverse events occurred in 37 (29%) of 127 patients. No treatment-related deaths were reported. INTERPRETATION: BYLieve showed activity of alpelisib plus fulvestrant with manageable toxicity in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer, after progression on a CDK4/6 inhibitor plus an aromatase inhibitor. FUNDING: Novartis Pharmaceuticals.
引用
- Rugo HS, Lerebours F, Ciruelos E, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2024. PMID: 39637900. doi:10.1016/S1470-2045(24)00673-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。